Document Detail


Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.
MedLine Citation:
PMID:  15151265     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients on chronic hemodialysis often suffer from severe anemia, the outcome of iron deficiency and inadequate response to erythropoietin. Antihypertensive treatment with captopril worsens anemia, erythropoietin production and iron balance in hemodialysis patients. We investigated the possibility that iron chelation by captopril in the blood may result in elimination of iron-captopril complexes during hemodialysis, thus minimizing the effect of both medications. METHODS: Twelve hypertensive hemodialysis patients (group 1) were treated with 12.5 mg/day captopril, while their 12 counterparts received 1.25 mg/day ramipril. Following two weeks of treatment and two weeks of "washout", captopril in group 1 was substituted with ramipril and ramipril in group 2 was replaced by captopril for an additional two week period. Blood and dialysate samples were procured at the beginning and the end of the dialysis, for iron, aluminum, transferin, ferritin, hemoglobin (Hb) and hematocrit (Htc) determination. RESULTS: Iron, ferritin, transferin, Hb and Htc were decreased in the captopril-treated group 1. They similarly decreased in group 2 following replacement of ramipril by captopril for an additional period of two weeks. Significant amounts of iron were detected in dialysates of captopril, but not ramipril-treated patients. At the end of the dialysis, iron content was further increased in dialysates of the captopril-treated groups. CONCLUSIONS: 1) Captopril-chelated iron is eliminated in dialysis fluid during the dialysis session, apparently contributing to captopril-related anemia in patients on chronic hemodialysis. 2) Antihypertensive treatment with angiotensin converting enzyme (ACE) inhibitors other than captopril might prove advantageous for this patient category.
Authors:
Zhan Averbukh; Sylvia Berman; Elena Kishinevsky; Leonid Feldman; Mirel Cohn; Micha Rapoport; Elena Galperin; Victor Dishi; Joshua Weissgarten
Related Documents :
11314805 - Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesi...
1473095 - Efficacy of capd as the primary treatment for end-stage renal failure in children.
10603115 - Neurodevelopmental outcome of children initiating peritoneal dialysis in early infancy.
1232995 - Preliminary results obtained with short dialysis schedules.
19035975 - Incidence of bleeding lesions within reach of conventional upper and lower endoscopes i...
22878405 - Effects of pitavastatin on cardiac structure and function and on prevention of atrial f...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of nephrology     Volume:  17     ISSN:  1121-8428     ISO Abbreviation:  J. Nephrol.     Publication Date:    2004 Jan-Feb
Date Detail:
Created Date:  2004-05-20     Completed Date:  2004-06-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9012268     Medline TA:  J Nephrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  101-6     Citation Subset:  IM    
Affiliation:
Nephrology Division, Assaf Harofeh Medical Center, Zerifin, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / blood,  etiology
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  metabolism*,  therapeutic use
Antihypertensive Agents / adverse effects,  metabolism*,  therapeutic use
Captopril / adverse effects,  metabolism*,  therapeutic use
Ferritins / blood
Hematocrit
Hemodialysis Solutions / chemistry
Hemoglobins / analysis
Humans
Hypertension / complications,  drug therapy
Iron / blood*
Iron Chelating Agents
Kidney Failure, Chronic / blood*,  complications,  therapy
Ramipril / adverse effects,  metabolism,  therapeutic use
Renal Dialysis*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Hemodialysis Solutions; 0/Hemoglobins; 0/Iron Chelating Agents; 62571-86-2/Captopril; 7439-89-6/Iron; 87333-19-5/Ramipril; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High doses of intravenous calcitriol in the treatment of severe secondary hyperparathyroidism.
Next Document:  The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional ir...